Terms: = Lymphoma AND BLM, MGC131620, 641, ENSG00000197299, MGC131618, RECQ2, RECQL2, RECQL3, MGC126616, BS AND Treatment
68 results:
1. treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia.
Pepeler MS; Tıglıoglu M; Dagdas S; Ozhamamcıoglu E; Han U; Albayrak A; Aydın MS; Korkmaz G; Pamukcuoğlu M; Ceran F; Albayrak M; Ozet G
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e161-e167. PubMed ID: 38342726
[TBL] [Abstract] [Full Text] [Related]
3. treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Shimomura Y; Sawa K; Imai T; Ihara Y; Yoshida H; Shintani A
Cancer Sci; 2024 Mar; 115(3):926-936. PubMed ID: 38148717
[TBL] [Abstract] [Full Text] [Related]
4. Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Elsayad K; Weishaupt C; Moustakis C; Danzer MF; Müller EC; Rolf D; Stranzenbach R; Livingstone E; Booken N; Stadler R; Eich HT
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):164-170. PubMed ID: 36893819
[TBL] [Abstract] [Full Text] [Related]
5. [Study on bone microstructure and pathology of type L2 and L3 osteonecrosis of the femoral head specimens classified by China-Japan Friendship Hospital classification based on "three-columns structure"].
Gao R; Xia X; Liu J; Yuan Z; Huan D; Shen J
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2022 Aug; 36(8):1003-1010. PubMed ID: 35979793
[TBL] [Abstract] [Full Text] [Related]
6. Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma.
Shimano R; Yamamoto H; Nasu I; Kashiwamura Y; Yamamoto G; Uchida N; Taniguchi S; Hayashi M; Ito T
Int J Hematol; 2022 Dec; 116(6):856-862. PubMed ID: 35976562
[TBL] [Abstract] [Full Text] [Related]
7. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Sancho JM; Marín-Niebla A; Fernández S; Capote FJ; Cañigral C; Grande C; Donato E; Zeberio I; Puerta JM; Rivas A; Pérez-Ceballos E; Vale A; Martín García-Sancho A; Salar A; González-Barca E; Teruel A; Pastoriza C; Conde-Royo D; Sánchez-García J; Barrenetxea C; Arranz R; Hernández-Rivas JÁ; Ramírez MJ; Jiménez A; Rubio-Azpeitia E
Int J Hematol; 2022 Sep; 116(3):381-392. PubMed ID: 35551632
[TBL] [Abstract] [Full Text] [Related]
8. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
[TBL] [Abstract] [Full Text] [Related]
9. Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.
Alrawashdh N; McBride A; Slack M; Persky D; Andritsos L; Abraham I
J Manag Care Spec Pharm; 2022 Apr; 28(4):390-400. PubMed ID: 35332792
[No Abstract] [Full Text] [Related]
10. ASCEND-7: Efficacy and Safety of Ceritinib treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Chow LQM; Barlesi F; Bertino EM; van den Bent MJ; Wakelee HA; Wen PY; Chiu CH; Orlov S; Chiari R; Majem M; McKeage M; Yu CJ; Garrido P; Hurtado FK; Arratia PC; Song Y; Branle F; Shi M; Kim DW
Clin Cancer Res; 2022 Jun; 28(12):2506-2516. PubMed ID: 35091443
[TBL] [Abstract] [Full Text] [Related]
11. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract] [Full Text] [Related]
12. Differential Impact of
O'Donohue T; Gulati N; Mauguen A; Kushner BH; Shukla N; Rodriguez-Sanchez MI; Bouvier N; Roberts S; Basu E; Cheung NK; Modak S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250410
[TBL] [Abstract] [Full Text] [Related]
13. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Komrokji R; Al Ali N; Padron E; Lancet J; Nazha A; Steensma D; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Sallman D
Leuk Lymphoma; 2021 Nov; 62(11):2762-2767. PubMed ID: 34114922
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center].
Jia YC; Lu J; Qiang WT; Li L; Liu J; Jiang H; Fu WJ; Du J
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1020-1024. PubMed ID: 33445850
[No Abstract] [Full Text] [Related]
15. Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma.
Rodríguez Taroco MG; Cuña EG; Pages C; Schelotto M; González-Sprinberg GA; Castillo LA; Alonso O
Nucl Med Commun; 2021 Mar; 42(3):306-314. PubMed ID: 33306628
[TBL] [Abstract] [Full Text] [Related]
16. [Deleted in lymphocytic leukemia 1 promoted proliferation and apoptosis of nephroblastoma cells through regulating miR-513a-5p and RANBP2 pathway].
Zhao JL; Zhao LL; Niu WZ; Ding XC; Zhang WL
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):849-855. PubMed ID: 33113626
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract] [Full Text] [Related]
18. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Evens AM; Danilov A; Jagadeesh D; Sperling A; Kim SH; Vaca R; Wei C; Rector D; Sundaram S; Reddy N; Lin Y; Farooq U; D'Angelo C; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Yazdy M; Rabinovich E; Varma G; Karmali R; Mian A; Savani M; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein AK; Blum KA; Boughan KM; Smith SE; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Ramdial J; Maliske SM; Epperla N; Venugopal P; Feldman TA; Smith SD; Stadnik A; David KA; Naik S; Lossos IS; Lunning MA; Caimi P; Kamdar M; Palmisiano N; Bachanova V; Portell CA; Phillips T; Olszewski AJ; Alderuccio JP
Blood; 2021 Jan; 137(3):374-386. PubMed ID: 32663292
[TBL] [Abstract] [Full Text] [Related]
19. Redox reaction and clinical outcome of primary diffuse large B-cell lymphoma of the central nervous system: Prognostic role of metabolic and textural parameters of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/computed tomography in a small patient cohort.
Tsuchiya J; Yoneyama T; Ohtake M; Tateishi K; Bae H; Kishino M; Tateishi U
Nucl Med Commun; 2020 Jun; 41(6):567-574. PubMed ID: 32371672
[TBL] [Abstract] [Full Text] [Related]
20. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.
Hoylman E; Brown A; Perissinotti AJ; Marini BL; Pianko M; Ye JC; Campagnaro E; Nachar VR
Leuk Lymphoma; 2020 Mar; 61(3):691-698. PubMed ID: 31739729
[TBL] [Abstract] [Full Text] [Related]
[Next]
